Barinthus Biotherapeutics

Q2 FY2026 EarningsQ2 FY26 results beat consensus on earnings but showed a continued absence of revenue, in line with expectations for a clinical-stage biopharmaceutical company. GAAP EPS of -$0.26 significantly exceeded the consensus estimate of -$0.36, primarily driven by a sharp 53% YoY reduction in total operating expenses following strategic reprioritization and U.K. facility closures. While the core VTP-1000 program saw a $1.2M spend increase, this was more than offset by a $2.4M reduction in legacy asset expenditure. Management remains focused on the pending Clywedog merger, expected to close in H2 2026.